Neuronetics, Inc. Q4 2025 Earnings Call Summary

<h3>Strategic Performance and Operational Evolution</h3>
<ul>
<li> <p class="yf-1fy9kyt">Achieved the critical milestone of positive operating cash flow in Q4 2025, validating the strategic thesis of the Greenbrook acquisition through revenue growth and expense discipline.</p></li>
<li> <p class="yf-1fy9kyt">Delivered 23% adjusted pro forma revenue growth driven by record capital shipments and a 28% increase in clinic revenue, reflecting successful integration of the national care delivery network.</p></li>
<li> <p class="yf-1fy9kyt">Realigned the NeuroStar capital sales team to focus on 'TMS-ready' accounts—practices with existing staff and insurance credentialing—to accelerate the timeline from system purchase to first patient treatment.</p></li>
<li> <p class="yf-1fy9kyt">Expanded the referring provider network by 25% year-over-year through a Regional Account Manager program that completed over 47,000 physician outreach activities in 2025.</p></li>
<li> <p class="yf-1fy9kyt">Optimized clinic economics by implementing a disciplined, state-by-state approach to SPRAVATO billing, balancing 'buy-and-bill' versus 'administer-and-observe' models based on payer dynamics.</p></li>
<li> <p class="yf-1fy9kyt">Leveraged internal infrastructure to launch a B2B service model, providing benefits investigation and patient management support to external national enterprise accounts like Transformations Care Network.</p></li>
</ul>
<h3>2026 Strategic Outlook and Growth Initiatives</h3>
<ul>
<li> <p class="yf-1fy9kyt">Projecting 2026 total revenue between $160 million and $166 million, with clinic business growth expected in the double digits to mid-teens.</p></li>
<li> <p class="yf-1fy9kyt">Implementing efficiency initiatives to reach an annualized operating expense run rate of less than $100 million by the fourth quarter of 2026.</p></li>
<li> <p class="yf-1fy9kyt">Anticipating positive operating cash flow for the full second half of 2026, following typical first-quarter seasonality and annual incentive outlays.</p></li>
<li> <p class="yf-1fy9kyt">Piloting new capital acquisition models in Q1 2026 to provide flexible technology access for diverse customer segments beyond traditional purchase structures.</p></li>
<li> <p class="yf-1fy9kyt">Preparing for a potential 2027 commercial launch of COMP360 psilocybin therapy, utilizing existing REMS-compliant infrastructure and clinical staff at Greenbrook locations.</p></li>
</ul>
<h3>Structural Changes and Risk Factors</h3>
<ul>
<li> <p class="yf-1fy9kyt">Announced a leadership transition with Dan Reavers appointed as President and CEO, effective March 23, 2026, to lead the company's next scaling phase.</p></li>
<li> <p class="yf-1fy9kyt">Amended the debt agreement with Perceptive in March 2026, including a $5.0 million principal paydown to reduce interest expense and optimize the balance sheet.</p></li>
<li> <p class="yf-1fy9kyt">Disclosed an ongoing investigation by the U.S. Attorney's Office in Florida regarding Greenbrook's billing practices prior to its acquisition by Neuronetics.</p></li>
<li> <p class="yf-1fy9kyt">Noted that Q1 2026 guidance reflects typical seasonality where patient volumes and capital budgets are historically at their lowest annual levels.</p></li>
</ul>